{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:56:25Z","timestamp":1786985785858,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Teaching Staff Training Program of Selcuk University","award":["2016-OYP-002"],"award-info":[{"award-number":["2016-OYP-002"]}]},{"name":"Selcuk University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.cca.2019.07.025","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:06:03Z","timestamp":1563966363000},"page":"120-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia"],"prefix":"10.1016","volume":"497","author":[{"given":"Duygu Eryavuz","family":"Onmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedat","family":"Abusoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir","family":"Basturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Dagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Bagci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguzhan","family":"Tok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsum","family":"Abusoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2019.07.025_bb0005","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.cca.2019.07.025_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2019.07.025_bb0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.cca.2019.07.025_bb0020","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.cca.2019.07.025_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","author":"Guilhot","year":"2004","journal-title":"Oncologist."},{"key":"10.1016\/j.cca.2019.07.025_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2019.07.025_bb0035","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.cca.2019.07.025_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005488","article-title":"A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment","volume":"95","author":"Yin","year":"2016","journal-title":"Medicine."},{"key":"10.1016\/j.cca.2019.07.025_bb0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cca.2019.07.025_bb0050","first-page":"315","article-title":"Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"4","author":"Mughal","year":"2010","journal-title":"Biologics."},{"key":"10.1016\/j.cca.2019.07.025_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4065\/84.2.161","article-title":"Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?","volume":"84","author":"Jabbour","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cca.2019.07.025_bb0060","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FTD.0b013e318292b931","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring","volume":"35","author":"Josephs","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2019.07.025_bb0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cca.2019.07.025_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/bmc.2796","article-title":"Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib","volume":"27","author":"Birch","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.cca.2019.07.025_bb0075","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.cca.2019.07.025_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2011.09.012","article-title":"Development and clinical application of a LC-MS\/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma","volume":"413","author":"Gotze","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2019.07.025_bb0085","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cca.2019.07.025_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10989-012-9321-0","article-title":"Quantification of imatinib plasma levels in patients with chronic myeloid leukemia: comparison between HPLC\u2013UV and LC\u2013MS\/MS","volume":"19","author":"Caterino","year":"2013","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.cca.2019.07.025_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jchromb.2003.10.018","article-title":"Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules","volume":"800","author":"Ivanovic","year":"2004","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.cca.2019.07.025_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5581\/1516-8484.20130030","article-title":"Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance","volume":"35","author":"Rezende","year":"2013","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.cca.2019.07.025_bb0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/chromsci\/bmt037","article-title":"LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma","volume":"52","author":"Zhang","year":"2014","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.cca.2019.07.025_bb0115","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.92","article-title":"Clinical development of imatinib: an anticancer drug","volume":"2","author":"Goswami","year":"2016","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.cca.2019.07.025_bb0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cca.2009.10.007","article-title":"Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS\/MS","volume":"411","author":"Roth","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2019.07.025_bb0125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.leukres.2009.08.005","article-title":"Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods\u2019 comparison","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cca.2019.07.025_bb0130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma","volume":"877","author":"Francia","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.cca.2019.07.025_bb0135","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"27","author":"Titier","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2019.07.025_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.cca.2019.07.025_bb0145","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jpha.2017.07.009","article-title":"A validated UPLC-MS\/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma","volume":"7","author":"Zeng","year":"2017","journal-title":"J. Pharm. Anal."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119319758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119319758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:49:48Z","timestamp":1757861388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119319758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":28,"alternative-id":["S0009898119319758"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.07.025","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}